# A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

> **NCT05399888** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Biogen** · enrollment: 416 (actual)

## Conditions studied

- Mild Cognitive Impairment Due to Alzheimer's Disease
- Alzheimer's Disease Dementia

## Interventions

- **DRUG:** BIIB080
- **DRUG:** BIIB080-matching placebo

## Key facts

- **NCT ID:** NCT05399888
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-24
- **Primary completion:** 2026-05-14
- **Final completion:** 2029-01-08
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05399888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05399888, "A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05399888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*